The original mandate aimed to find a new direction for the world renowned International Herald Tribune just as both the World Wide Web was in its infancy, and the newspaper faced increased competition from international and regional editions of established newspapers and magazines such as The Economist, The Wall Street Journal, and The Financial Times.

To support the quality and defensibility of regulatory decision-making under the Canadian Environmental Protection Act, 1999 (CEPA), Health Canada engaged Risk Sciences International to coordinate an independent external peer review of the Draft Screening Assessment Report (DSAR) for Selected C3-C5 Alcohols, focusing specifically on tert-butanol (CAS RN 75-65-0). This group of substances had been prioritized for risk assessment based on potential human health concerns.

An independent regulatory organization responsible for oversight of Alberta’s safety codes system sought to strengthen its capacity for risk-based decision-making. The organization aimed to ensure that regulatory actions—particularly in the area of petroleum storage tanks—were guided by clear, evidence-based prioritization methods that protect public safety while making effective use of resources. The project began with…

A large number of domestic and foreign animal diseases with zoonotic health impacts to humans must be managed carefully to prevent disease transmission and spread. Risk management decisions often involve the comparison of different types of risk and the cost-effectiveness of different control measures for reducing risk. This requires that different types of risk be assessed in a consistent manner to allow cross-comparisons. The use of disability adjusted life years (DALYs) as a measure of the burden of human disease from domestic and foreign animal pathogens was completed for several zoonoses in Canada.

In response to public and ministerial concerns about the timeliness and adequacy of information shared during a major prescription drug recall, Health Canada commissioned an independent review to assess its response to the event. The situation involved a recall of the oral contraceptive Alysena, issued due to packaging issues that altered the intended dosing sequence and raised questions about potential unintended health risks.

To support the evaluation of a new veterinary pharmaceutical product intended for use in bovines, a scientific review was requested of submitted toxicological data related to the active compound LY488756. This compound, proposed under the product name Experior, had been advanced for registration based on its claimed selective action on β3-adrenergic receptors and a lack of mutagenic, carcinogenic, or teratogenic effects. Given its potential entry into the human food supply via meat residues, an independent expert analysis of the submission was deemed necessary to determine its safety.